Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Inclusion Criteria

• •≥1 year of age at the day of screening visit.
• •Either no evidence of viral infection or viremia, or asymptomatic, viral infection with 3 or fewer viruses of interest at time of screening
• •Within 15 and 42 days of receiving a first allogeneic HCT and have demonstrated clinical engraftment
• •Meet one or more of the following criteria at the time of randomization:
• •* Related (sibling) donor with at least one mismatch at one of these HLA-gene loci: HLA-A, -B or -DR
• •* Haploidentical donor
• •* Unrelated donor with at least one mismatch at one of these HLA-gene loci: HLA-A, -B, -C, or -DR
• •* Use of umbilical cord blood as stem cell source
• •* Ex vivo graft manipulation resulting in T cell depletion
• •* Lymphocyte Count \<180/mm3 and/or cluster of differentiation 4 (CD4) Count \<50/mm3